Cite
HARVARD Citation
Vertechy, L. et al. (2023). Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study. International journal of gynecological cancer. 33 (2), pp. 243-249. [Online].